Neurocrine Biosciences, Inc. (NBIX)
NASDAQ: NBIX · Real-Time Price · USD
155.51
+1.29 (0.84%)
At close: Dec 5, 2025, 4:00 PM EST
156.50
+0.99 (0.64%)
After-hours: Dec 5, 2025, 6:57 PM EST
Neurocrine Biosciences Stock Forecast
Stock Price Forecast
The 19 analysts with 12-month price forecasts for Neurocrine Biosciences stock have an average target of 173.79, with a low estimate of 115 and a high estimate of 203. The average target predicts an increase of 11.75% from the current stock price of 155.51.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Neurocrine Biosciences stock from 19 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jul '25 | Aug '25 | Sep '25 | Oct '25 | Nov '25 | Dec '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 10 | 10 | 9 | 10 | 10 | 11 |
| Buy | 10 | 8 | 7 | 7 | 7 | 7 |
| Hold | 2 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 22 | 19 | 17 | 18 | 18 | 19 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| TD Cowen | TD Cowen | Strong Buy Maintains $175 → $200 | Strong Buy | Maintains | $175 → $200 | +28.61% | Dec 5, 2025 |
| Morgan Stanley | Morgan Stanley | Buy Maintains $178 → $173 | Buy | Maintains | $178 → $173 | +11.25% | Nov 11, 2025 |
| JP Morgan | JP Morgan | Buy Maintains $171 → $179 | Buy | Maintains | $171 → $179 | +15.11% | Nov 3, 2025 |
| Truist Securities | Truist Securities | Strong Buy Reiterates $165 → $172 | Strong Buy | Reiterates | $165 → $172 | +10.60% | Oct 30, 2025 |
| Canaccord Genuity | Canaccord Genuity | Strong Buy Maintains $160 → $164 | Strong Buy | Maintains | $160 → $164 | +5.46% | Oct 29, 2025 |
Financial Forecast
Revenue This Year
2.92B
from 2.36B
Increased by 23.76%
Revenue Next Year
3.44B
from 2.92B
Increased by 18.01%
EPS This Year
5.14
from 3.29
Increased by 56.20%
EPS Next Year
6.89
from 5.14
Increased by 34.01%
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 3.0B | 3.8B | ||||
| Avg | 2.9B | 3.4B | ||||
| Low | 2.8B | 3.0B |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 28.6% | 31.5% | ||||
| Avg | 23.8% | 18.0% | ||||
| Low | 17.1% | 4.4% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 5.82 | 9.45 | ||||
| Avg | 5.14 | 6.89 | ||||
| Low | 4.46 | 3.55 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 76.8% | 83.9% | ||||
| Avg | 56.2% | 34.0% | ||||
| Low | 35.5% | -31.0% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.